1 2325 144 TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH IYENGAR YOGA AND COHERENT BREATHING: A RANDOMIZED CONTROLLED DOSING STUDY. OBJECTIVES: THE AIMS OF THIS STUDY WERE TO ASSESS THE EFFECTS OF AN INTERVENTION OF IYENGAR YOGA AND COHERENT BREATHING AT FIVE BREATHS PER MINUTE ON DEPRESSIVE SYMPTOMS AND TO DETERMINE OPTIMAL INTERVENTION YOGA DOSING FOR FUTURE STUDIES IN INDIVIDUALS WITH MAJOR DEPRESSIVE DISORDER (MDD). METHODS: SUBJECTS WERE RANDOMIZED TO THE HIGH-DOSE GROUP (HDG) OR LOW-DOSE GROUP (LDG) FOR A 12-WEEK INTERVENTION OF THREE OR TWO INTERVENTION CLASSES PER WEEK, RESPECTIVELY. ELIGIBLE SUBJECTS WERE 18-64 YEARS OLD WITH MDD, HAD BASELINE BECK DEPRESSION INVENTORY-II (BDI-II) SCORES >/=14, AND WERE EITHER ON NO ANTIDEPRESSANT MEDICATIONS OR ON A STABLE DOSE OF ANTIDEPRESSANTS FOR >/=3 MONTHS. THE INTERVENTION INCLUDED 90-MIN CLASSES PLUS HOMEWORK. OUTCOME MEASURES WERE BDI-II SCORES AND INTERVENTION COMPLIANCE. RESULTS: FIFTEEN HDG (MAGE = 38.4 +/- 15.1 YEARS) AND 15 LDG (MAGE = 34.7 +/- 10.4 YEARS) SUBJECTS COMPLETED THE INTERVENTION. BDI-II SCORES AT SCREENING AND COMPLIANCE DID NOT DIFFER BETWEEN GROUPS (P = 0.26). BDI-II SCORES DECLINED SIGNIFICANTLY FROM SCREENING (24.6 +/- 1.7) TO WEEK 12 (6.0 +/- 3.8) FOR THE HDG (-18.6 +/- 6.6; P < 0.001), AND FROM SCREENING (27.7 +/- 2.1) TO WEEK 12 (10.1 +/- 7.9) IN THE LDG (-17.7 +/- 9.3; P < 0.001). THERE WERE NO SIGNIFICANT DIFFERENCES BETWEEN GROUPS, BASED ON RESPONSE (I.E., >50% DECREASE IN BDI-II SCORES; P = 0.65) FOR THE HDG (13/15 SUBJECTS) AND LDG (11/15 SUBJECTS) OR REMISSION (I.E., NUMBER OF SUBJECTS WITH BDI-II SCORES <14; P = 1.00) FOR THE HDG (14/15 SUBJECTS) AND LDG (13/15 SUBJECTS) AFTER THE 12-WEEK INTERVENTION, ALTHOUGH A GREATER NUMBER OF SUBJECTS IN THE HDG HAD 12-WEEK BDI-II SCORES </=10 (P = 0.04). CONCLUSION: DURING THIS 12-WEEK INTERVENTION OF YOGA PLUS COHERENT BREATHING, DEPRESSIVE SYMPTOMS DECLINED SIGNIFICANTLY IN PATIENTS WITH MDD IN BOTH THE HDG AND LDG. BOTH GROUPS SHOWED COMPARABLE COMPLIANCE AND CLINICAL IMPROVEMENTS, WITH MORE SUBJECTS IN THE HDG EXHIBITING BDI-II SCORES </=10 AT WEEK 12.	2017	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
2  327  44 ANTIDEPRESSANT EFFICACY OF SUDARSHAN KRIYA YOGA (SKY) IN MELANCHOLIA: A RANDOMIZED COMPARISON WITH ELECTROCONVULSIVE THERAPY (ECT) AND IMIPRAMINE. BACKGROUND: SUDARSHAN KRIYA YOGA (SKY) IS A PROCEDURE THAT INVOLVES ESSENTIALLY RHYTHMIC HYPERVENTILATION AT DIFFERENT RATES OF BREATHING. THE ANTIDEPRESSANT EFFICACY OF SKY WAS DEMONSTRATED IN DYSTHYMIA IN A PROSPECTIVE, OPEN CLINICAL TRIAL. THIS STUDY COMPARED THE RELATIVE ANTIDEPRESSANT EFFICACY OF SKY IN MELANCHOLIA WITH TWO OF THE CURRENT STANDARD TREATMENTS, ELECTROCONVULSIVE THERAPY (ECT) AND IMIPRAMINE (IMN). METHODS: CONSENTING, UNTREATED MELANCHOLIC DEPRESSIVES (N=45) WERE HOSPITALIZED AND RANDOMIZED EQUALLY INTO THREE TREATMENT GROUPS. THEY WERE ASSESSED AT RECRUITMENT AND WEEKLY THEREAFTER FOR FOUR WEEKS. RESULTS: SIGNIFICANT REDUCTIONS IN THE TOTAL SCORES ON BECK DEPRESSION INVENTORY (BDI) AND HAMILTON RATING SCALE FOR DEPRESSION (HRSD) OCCURRED ON SUCCESSIVE OCCASIONS IN ALL THREE GROUPS. THE GROUPS, HOWEVER, DID NOT DIFFER. SIGNIFICANT INTERACTION BETWEEN THE GROUPS AND OCCASION OF ASSESSMENT OCCURRED. AT WEEK THREE, THE SKY GROUP HAD HIGHER SCORES THAN THE ECT GROUP BUT WAS NOT DIFFERENT FROM THE IMN GROUP. REMISSION (TOTAL HRSD SCORE OF SEVEN OR LESS) RATES AT THE END OF THE TRIAL WERE 93, 73 AND 67% IN THE ECT, IMN AND SKY GROUPS, RESPECTIVELY. NO CLINICALLY SIGNIFICANT SIDE EFFECTS WERE OBSERVED. DISCUSSION: WITHIN THE LIMITATIONS OF THE DESIGN (LACK OF DOUBLE BLIND CONDITIONS), IT CAN BE CONCLUDED THAT, ALTHOUGH INFERIOR TO ECT, SKY CAN BE A POTENTIAL ALTERNATIVE TO DRUGS IN MELANCHOLIA AS A FIRST LINE TREATMENT.	2000	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
3 2318  50 TREATING MAJOR DEPRESSION WITH YOGA: A PROSPECTIVE, RANDOMIZED, CONTROLLED PILOT TRIAL. BACKGROUND: CONVENTIONAL PHARMACOTHERAPIES AND PSYCHOTHERAPIES FOR MAJOR DEPRESSION ARE ASSOCIATED WITH LIMITED ADHERENCE TO CARE AND RELATIVELY LOW REMISSION RATES. YOGA MAY OFFER AN ALTERNATIVE TREATMENT OPTION, BUT RIGOROUS STUDIES ARE FEW. THIS RANDOMIZED CONTROLLED TRIAL WITH BLINDED OUTCOME ASSESSORS EXAMINED AN 8-WEEK HATHA YOGA INTERVENTION AS MONO-THERAPY FOR MILD-TO-MODERATE MAJOR DEPRESSION. METHODS: INVESTIGATORS RECRUITED 38 ADULTS IN SAN FRANCISCO MEETING CRITERIA FOR MAJOR DEPRESSION OF MILD-TO-MODERATE SEVERITY, PER STRUCTURED PSYCHIATRIC INTERVIEW AND SCORES OF 14-28 ON BECK DEPRESSION INVENTORY-II (BDI). AT SCREENING, INDIVIDUALS ENGAGED IN PSYCHOTHERAPY, ANTIDEPRESSANT PHARMACOTHERAPY, HERBAL OR NUTRACEUTICAL MOOD THERAPIES, OR MIND-BODY PRACTICES WERE EXCLUDED. PARTICIPANTS WERE 68% FEMALE, WITH MEAN AGE 43.4 YEARS (SD = 14.8, RANGE = 22-72), AND MEAN BDI SCORE 22.4 (SD = 4.5). TWENTY PARTICIPANTS WERE RANDOMIZED TO 90-MINUTE HATHA YOGA PRACTICE GROUPS TWICE WEEKLY FOR 8 WEEKS. EIGHTEEN PARTICIPANTS WERE RANDOMIZED TO 90-MINUTE ATTENTION CONTROL EDUCATION GROUPS TWICE WEEKLY FOR 8 WEEKS. CERTIFIED YOGA INSTRUCTORS DELIVERED BOTH INTERVENTIONS AT A UNIVERSITY CLINIC. PRIMARY OUTCOME WAS DEPRESSION SEVERITY, MEASURED BY BDI SCORES EVERY 2 WEEKS FROM BASELINE TO 8 WEEKS. SECONDARY OUTCOMES WERE SELF-EFFICACY AND SELF-ESTEEM, MEASURED BY SCORES ON THE GENERAL SELF-EFFICACY SCALE (GSES) AND ROSENBERG SELF-ESTEEM SCALE (RSES) AT BASELINE AND AT 8 WEEKS. RESULTS: IN INTENT-TO-TREAT ANALYSIS, YOGA PARTICIPANTS EXHIBITED SIGNIFICANTLY GREATER 8-WEEK DECLINE IN BDI SCORES THAN CONTROLS (P-VALUE = 0.034). IN SUB-ANALYSES OF PARTICIPANTS COMPLETING FINAL 8-WEEK MEASURES, YOGA PARTICIPANTS WERE MORE LIKELY TO ACHIEVE REMISSION, DEFINED PER FINAL BDI SCORE </= 9 (P-VALUE = 0.018). EFFECT SIZE OF YOGA IN REDUCING BDI SCORES WAS LARGE, PER COHEN'S D = -0.96 [95%CI, -1.81 TO -0.12]. INTERVENTION GROUPS DID NOT DIFFER SIGNIFICANTLY IN 8-WEEK CHANGE SCORES FOR EITHER THE GSES OR RSES. CONCLUSION: IN ADULTS WITH MILD-TO-MODERATE MAJOR DEPRESSION, AN 8-WEEK HATHA YOGA INTERVENTION RESULTED IN STATISTICALLY AND CLINICALLY SIGNIFICANT REDUCTIONS IN DEPRESSION SEVERITY. TRIAL REGISTRATION: CLINICALTRIALS.GOV NCT01210651.	2017	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
4  232  40 A SYSTEMATIC REVIEW OF YOGA FOR MAJOR DEPRESSIVE DISORDER. BACKGROUND: THE PURPOSE OF THIS REVIEW WAS TO INVESTIGATE THE EFFICACY AND SAFETY OF YOGA INTERVENTIONS IN TREATING PATIENTS WITH MAJOR DEPRESSIVE DISORDER. METHODS: MEDLINE, SCOPUS, AND THE COCHRANE LIBRARY WERE SCREENED THROUGH DECEMBER 2016. RANDOMIZED CONTROLLED TRIALS (RCTS) COMPARING YOGA TO INACTIVE OR ACTIVE COMPARATORS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER WERE ELIGIBLE. PRIMARY OUTCOMES INCLUDED REMISSION RATES AND SEVERITY OF DEPRESSION. ANXIETY AND ADVERSE EVENTS WERE SECONDARY OUTCOMES. RISK OF BIAS WAS ASSESSED USING THE COCHRANE TOOL. RESULTS: SEVEN RCTS WITH 240 PARTICIPANTS WERE INCLUDED. RISK OF BIAS WAS UNCLEAR FOR MOST RCTS. COMPARED TO AEROBIC EXERCISE, NO SHORT- OR MEDIUM-TERM GROUP DIFFERENCES IN DEPRESSION SEVERITY WAS FOUND. HIGHER SHORT-TERM DEPRESSION SEVERITY WAS FOUND FOR YOGA COMPARED TO ELECTRO-CONVULSIVE THERAPY; REMISSION RATES DID NOT DIFFER BETWEEN GROUPS. NO SHORT-TERM GROUP DIFFERENCES OCCURRED WHEN YOGA WAS COMPARED TO ANTIDEPRESSANT MEDICATION. CONFLICTING EVIDENCE WAS FOUND WHEN YOGA WAS COMPARED TO ATTENTION-CONTROL INTERVENTIONS, OR WHEN YOGA AS AN ADD-ON TO ANTIDEPRESSANT MEDICATION WAS COMPARED TO MEDICATION ALONE. ONLY TWO RCTS ASSESSED ADVERSE EVENTS AND REPORTED THAT NO TREATMENT-RELATED ADVERSE EVENTS WERE REPORTED. LIMITATIONS: FEW RCTS WITH LOW SAMPLE SIZE. CONCLUSIONS: THIS REVIEW FOUND SOME EVIDENCE FOR POSITIVE EFFECTS BEYOND PLACEBO AND COMPARABLE EFFECTS COMPARED TO EVIDENCE-BASED INTERVENTIONS. HOWEVER, METHODOLOGICAL PROBLEMS AND THE UNCLEAR RISK-BENEFIT RATIO PRECLUDE DEFINITIVE RECOMMENDATIONS FOR OR AGAINST YOGA AS AN ADJUNCT TREATMENT FOR MAJOR DEPRESSIVE DISORDER. LARGER AND ADEQUATELY POWERED RCTS USING NON-INFERIORITY DESIGNS ARE NEEDED.	2017	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
5  168  56 A RANDOMIZED CONTROLLED DOSING STUDY OF IYENGAR YOGA AND COHERENT BREATHING FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER: IMPACT ON SUICIDAL IDEATION AND SAFETY FINDINGS. BACKGROUND: YOGA INTERVENTIONS OFFER PROMISE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD), YET THEIR SAFETY AND POTENTIAL IMPACT ON SUICIDAL IDEATION (SI) HAVE NOT BEEN WELL DOCUMENTED. THIS STUDY EVALUATED THE SAFETY OF A RANDOMIZED CONTROLLED DOSE-FINDING TRIAL OF IYENGAR YOGA PLUS COHERENT BREATHING FOR INDIVIDUALS WITH MDD, AS WELL AS THE POTENTIAL EFFECTS OF THE INTERVENTION ON SI WITHOUT INTENT. METHODS: PARTICIPANTS WITH BECK DEPRESSION INVENTORY-II (BDI-II) SCORES >/=14 AND A DIAGNOSIS OF MDD (USING DSM-IV CRITERIA) WERE RANDOMIZED TO EITHER A LOW DOSE GROUP (LDG) OR HIGH DOSE GROUP (HDG) AND RECEIVED A 12-WEEK MANUALIZED INTERVENTION. THE LDG INCLUDED TWO 90-MIN YOGA CLASSES PLUS THREE 30-MIN HOMEWORK SESSIONS WEEKLY. THE HDG OFFERED THREE 90-MIN CLASSES PLUS FOUR 30-MIN HOMEWORK SESSIONS WEEKLY. RESULTS: THIRTY-TWO INDIVIDUALS WITH MDD WERE RANDOMIZED, OF WHICH 30 COMPLETED THE PROTOCOL. AT SCREENING, SI WITHOUT INTENT WAS ENDORSED ON THE BDI-II BY 9 PARTICIPANTS; AFTER COMPLETING THE INTERVENTION, 8 OUT OF 9 REPORTED RESOLUTION OF SI. THERE WERE 17 ADVERSE EVENTS POSSIBLY-RELATED AND 15 DEFINITELY-RELATED TO THE INTERVENTION. THE MOST COMMON PROTOCOL-RELATED ADVERSE EVENT WAS MUSCULOSKELETAL PAIN, WHICH RESOLVED OVER THE COURSE OF THE STUDY. CONCLUSIONS: THE IYENGAR YOGA PLUS COHERENT BREATHING INTERVENTION WAS ASSOCIATED WITH THE RESOLUTION OF SI IN 8 OUT OF 9 PARTICIPANTS, WITH MILD SIDE EFFECTS THAT WERE PRIMARILY MUSCULOSKELETAL IN NATURE. THIS PRELIMINARY EVIDENCE SUGGESTS THAT THIS INTERVENTION MAY REDUCE SI WITHOUT INTENT AND BE SAFE FOR USE IN THOSE WITH MDD.	2018	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
6 2568  36 YOGA FOR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS. BACKGROUND: MIND-BODY MEDICAL INTERVENTIONS ARE COMMONLY USED TO COPE WITH DEPRESSION AND YOGA IS ONE OF THE MOST COMMONLY USED MIND-BODY INTERVENTIONS. THE AIM OF THIS REVIEW WAS TO SYSTEMATICALLY ASSESS AND META-ANALYZE THE EFFECTIVENESS OF YOGA FOR DEPRESSION. METHODS: MEDLINE/PUBMED, SCOPUS, THE COCHRANE LIBRARY, PSYCINFO, AND INDMED WERE SEARCHED THROUGH JANUARY 2013. RANDOMIZED CONTROLLED TRIALS (RCTS) OF YOGA FOR PATIENTS WITH DEPRESSIVE DISORDERS AND INDIVIDUALS WITH ELEVATED LEVELS OF DEPRESSION WERE INCLUDED. MAIN OUTCOMES WERE SEVERITY OF DEPRESSION AND REMISSION RATES, SECONDARY OUTCOMES WERE ANXIETY, QUALITY OF LIFE, AND SAFETY. RESULTS: TWELVE RCTS WITH 619 PARTICIPANTS WERE INCLUDED. THREE RCTS HAD LOW RISK OF BIAS. REGARDING SEVERITY OF DEPRESSION, THERE WAS MODERATE EVIDENCE FOR SHORT-TERM EFFECTS OF YOGA COMPARED TO USUAL CARE (STANDARDIZED MEAN DIFFERENCE (SMD) = -0.69; 95% CONFIDENCE INTERVAL (CI) -0.99, -0.39; P < .001), AND LIMITED EVIDENCE COMPARED TO RELAXATION (SMD = -0.62; 95%CI -1.03, -0.22; P = .003), AND AEROBIC EXERCISE (SMD = -0.59; 95% CI -0.99, -0.18; P = .004). LIMITED EVIDENCE WAS FOUND FOR SHORT-TERM EFFECTS OF YOGA ON ANXIETY COMPARED TO RELAXATION (SMD = -0.79; 95% CI -1.3, -0.26; P = .004). SUBGROUP ANALYSES REVEALED EVIDENCE FOR EFFECTS IN PATIENTS WITH DEPRESSIVE DISORDERS AND IN INDIVIDUALS WITH ELEVATED LEVELS OF DEPRESSION. DUE TO THE PAUCITY AND HETEROGENEITY OF THE RCTS, NO META-ANALYSES ON LONG-TERM EFFECTS WERE POSSIBLE. NO RCT REPORTED SAFETY DATA. CONCLUSIONS: DESPITE METHODOLOGICAL DRAWBACKS OF THE INCLUDED STUDIES, YOGA COULD BE CONSIDERED AN ANCILLARY TREATMENT OPTION FOR PATIENTS WITH DEPRESSIVE DISORDERS AND INDIVIDUALS WITH ELEVATED LEVELS OF DEPRESSION.	2013	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
7   99  41 A PATIENT WITH ELECTROCONVULSIVE THERAPY-RESISTANT MAJOR DEPRESSIVE DISORDER WITH A FULL RESPONSE TO HEATED YOGA: A CASE REPORT. DEPRESSION REMAINS DIFFICULT TO TREAT AS A RESULT OF LESS THAN OPTIMAL EFFICACY AND TROUBLESOME SIDE EFFECTS OF ANTIDEPRESSANTS. THE AUTHORS PRESENT THE CASE OF A PATIENT WITH TREATMENT-RESISTANT DEPRESSION WITH MELANCHOLIC FEATURES WHO HAD PREVIOUSLY BEEN UNRESPONSIVE TO ELECTROCONVULSIVE THERAPY (ECT) PLUS AN ANTIDEPRESSANT REGIMEN BUT WHOSE CONDITION FULLY REMITTED WITH THE ADDITION OF A STANDARDIZED FORM OF HEATED HATHA YOGA (HY; BIKRAM YOGA) PRACTICED IN A ROOM HEATED TO 105 DEGREES F. THE PATIENT WAS A 28-YEAR-OLD WOMAN WHO UNDERWENT 8 WEEKS OF HY AS PART OF A RANDOMIZED CONTROLLED TRIAL OF HY FOR DEPRESSION WHILE CONTINUING HER ANTIDEPRESSANT TREATMENT. THE PATIENT WAS ASKED TO ATTEND A MINIMUM OF 2 WEEKLY, 90-MINUTE HY CLASSES. AFTER 8 WEEKS (12 CLASSES IN TOTAL), THE PATIENT NO LONGER MET THE CRITERIA FOR A MAJOR DEPRESSIVE EPISODE WITH MELANCHOLIC FEATURES, PER MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (MINI) CRITERIA. HER DEPRESSIVE SYMPTOMS HAD IMPROVED DRAMATICALLY, WITH INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY, CLINICIAN-RATED (IDS-C30), AND HAMILTON DEPRESSION RATING SCALE (HAM-D28) SCORES DECREASING FROM 28 AT BASELINE TO 3, AND FROM 28 AT BASELINE TO 4, RESPECTIVELY, INDICATING REMISSION. THIS PATIENT'S ECT-RESISTANT DEPRESSION REMITTED WITH THE ADDITION OF HY TO HER ANTIDEPRESSANT REGIMEN. BECAUSE OF HER YOUTH AND ATHLETICISM, THIS PATIENT WAS LIKELY WELL SUITED TO THIS RIGOROUS FORM OF YOGA. FURTHER RESEARCH IS NEEDED TO EXPLORE HY AS A POTENTIAL INTERVENTION FOR TREATMENT-RESISTANT DEPRESSION.	2021	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
8   91  46 A MULTICOMPONENT YOGA-BASED, BREATH INTERVENTION PROGRAM AS AN ADJUNCTIVE TREATMENT IN PATIENTS SUFFERING FROM GENERALIZED ANXIETY DISORDER WITH OR WITHOUT COMORBIDITIES. OBJECTIVES: THE AIM OF THIS STUDY IS TO EVALUATE THE EFFICACY AND TOLERABILITY OF SUDARSHAN KRIYA YOGA (SKY) COURSE IN GENERALIZED ANXIETY DISORDER (GAD) OUTPATIENTS, WHO AFTER EIGHT WEEKS OF AN APPROPRIATE DOSE OF TRADITIONAL THERAPY HAD NOT YET ACHIEVED REMISSION. SUBJECTS: THE ADULT PARTICIPANTS (18-65 YEARS) WERE OUTPATIENTS WITH A PRIMARY DIAGNOSIS OF GAD WITH OR WITHOUT COMORBIDITIES ON THE MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (MINI). PARTICIPANTS HAD A MINIMUM OF EIGHT WEEKS STANDARD TREATMENT WITH AN APPROPRIATE DOSE OF A STANDARD PRESCRIPTION ANXIOLYTIC, A CLINICIAN GLOBAL IMPRESSION-SEVERITY (CGI-S) SCORE OF 5-7, A HAMILTON ANXIETY SCALE (HAM-A) TOTAL SCORE >/=20 INCLUDING A SCORE OF >2 ON THE ANXIOUS MOOD AND TENSION ITEMS. MATERIALS AND METHODS: FORTY-ONE PATIENTS WERE ENROLLED IN AN OPEN-LABEL TRIAL OF THE SKY COURSE AS AN ADJUNCT TO STANDARD TREATMENT OF GAD AT THE START CLINIC FOR MOOD AND ANXIETY DISORDERS, A TERTIARY CARE MOOD AND ANXIETY DISORDER CLINIC IN TORONTO. THE SKY COURSE WAS ADMINISTERED OVER FIVE DAYS (22 H TOTAL). SUBJECTS WERE ENCOURAGED TO PRACTICE THE YOGA BREATHING TECHNIQUES AT HOME FOR 20 MIN PER DAY AFTER THE COURSE AND WERE OFFERED GROUP PRACTICE SESSIONS FOR 2 H ONCE A WEEK LED BY CERTIFIED YOGA INSTRUCTORS. THE PRIMARY OUTCOME MEASURE WAS THE MEAN CHANGE FROM PRE-TREATMENT ON THE HAM-A SCALE. PSYCHOLOGICAL MEASURES WERE OBTAINED AT BASELINE AND FOUR WEEKS AFTER COMPLETING THE INTERVENTION. RESULTS: THIRTY-ONE PATIENTS COMPLETED THE PROGRAM (MEAN AGE 42.6 +/- 13.3 YEARS). AMONG COMPLETERS, SIGNIFICANT REDUCTIONS OCCURRED IN THE PRE- AND POST-INTERVENTION MEAN HAM-A TOTAL SCORE (T=4.59; P<0.01) AND PSYCHIC SUBSCALE (T=5.00; P</=0.01). THE RESPONSE RATE WAS 73% AND THE REMISSION RATE 41% AS MEASURED ON THE HAM-A. CONCLUSION: THE RESULTS OF THIS SMALL PILOT TRIAL SUGGEST THAT THE SKY COURSE REPRESENTS A POTENTIALLY VALUABLE ADJUNCT TO STANDARD PHARMACOTHERAPY IN PATIENTS WITH GAD OR TREATMENT-RESISTANT GAD, AND WARRANTS FURTHER INVESTIGATION. IN PARTICULAR, CHANGES IN WORRY AND BODY SYMPTOMS SHOWED SIGNIFICANT IMPROVEMENTS THAT MAY FURTHER OUR UNDERSTANDING OF THE MECHANISM OF CHANGE IN THE TOLERANCE OF ANXIETY AND WORRY.	2012	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
9 2540  38 YOGA FOR ANXIETY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. YOGA HAS BECOME A POPULAR APPROACH TO IMPROVE EMOTIONAL HEALTH. THE AIM OF THIS REVIEW WAS TO SYSTEMATICALLY ASSESS AND META-ANALYZE THE EFFECTIVENESS AND SAFETY OF YOGA FOR ANXIETY. MEDLINE/PUBMED, SCOPUS, THE COCHRANE LIBRARY, PSYCINFO, AND INDMED WERE SEARCHED THROUGH OCTOBER 2016 FOR RANDOMIZED CONTROLLED TRIALS (RCTS) OF YOGA FOR INDIVIDUALS WITH ANXIETY DISORDERS OR ELEVATED LEVELS OF ANXIETY. THE PRIMARY OUTCOMES WERE ANXIETY AND REMISSION RATES, AND SECONDARY OUTCOMES WERE DEPRESSION, QUALITY OF LIFE, AND SAFETY. RISK OF BIAS WAS ASSESSED USING THE COCHRANE TOOL. EIGHT RCTS WITH 319 PARTICIPANTS (MEAN AGE: 30.0-38.5 YEARS) WERE INCLUDED. RISK OF SELECTION BIAS WAS UNCLEAR FOR MOST RCTS. META-ANALYSES REVEALED EVIDENCE FOR SMALL SHORT-TERM EFFECTS OF YOGA ON ANXIETY COMPARED TO NO TREATMENT (STANDARDIZED MEAN DIFFERENCE [SMD] = -0.43; 95% CONFIDENCE INTERVAL [CI] = -0.74, -0.11; P = .008), AND LARGE EFFECTS COMPARED TO ACTIVE COMPARATORS (SMD = -0.86; 95% CI = -1.56, -0.15; P = .02). SMALL EFFECTS ON DEPRESSION WERE FOUND COMPARED TO NO TREATMENT (SMD = -0.35; 95% CI = -0.66, -0.04; P = .03). EFFECTS WERE ROBUST AGAINST POTENTIAL METHODOLOGICAL BIAS. NO EFFECTS WERE FOUND FOR PATIENTS WITH ANXIETY DISORDERS DIAGNOSED BY DIAGNOSTIC AND STATISTICAL MANUAL CRITERIA, ONLY FOR PATIENTS DIAGNOSED BY OTHER METHODS, AND FOR INDIVIDUALS WITH ELEVATED LEVELS OF ANXIETY WITHOUT A FORMAL DIAGNOSIS. ONLY THREE RCTS REPORTED SAFETY-RELATED DATA BUT THESE INDICATED THAT YOGA WAS NOT ASSOCIATED WITH INCREASED INJURIES. IN CONCLUSION, YOGA MIGHT BE AN EFFECTIVE AND SAFE INTERVENTION FOR INDIVIDUALS WITH ELEVATED LEVELS OF ANXIETY. THERE WAS INCONCLUSIVE EVIDENCE FOR EFFECTS OF YOGA IN ANXIETY DISORDERS. MORE HIGH-QUALITY STUDIES ARE NEEDED AND ARE WARRANTED GIVEN THESE PRELIMINARY FINDINGS AND PLAUSIBLE MECHANISMS OF ACTION.	2018	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
10 1853  36 RANDOMISED CLINICAL TRIAL: YOGA VS WRITTEN SELF-CARE ADVICE FOR ULCERATIVE COLITIS. BACKGROUND: PERCEIVED STRESS SEEMS TO BE A RISK FACTOR FOR EXACERBATION OF ULCERATIVE COLITIS. YOGA HAS BEEN SHOWN TO REDUCE PERCEIVED STRESS. AIMS: TO ASSESS THE EFFICACY AND SAFETY OF YOGA FOR IMPROVING QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS. METHODS: A TOTAL OF 77 PATIENTS (75% WOMEN; 45.5 +/- 11.9 YEARS) WITH ULCERATIVE COLITIS IN CLINICAL REMISSION BUT IMPAIRED QUALITY OF LIFE WERE RANDOMLY ASSIGNED TO YOGA (12 SUPERVISED WEEKLY SESSIONS OF 90 MIN; N = 39) OR WRITTEN SELF-CARE ADVICE (N = 38). PRIMARY OUTCOME WAS DISEASE-SPECIFIC QUALITY OF LIFE (INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE). SECONDARY OUTCOMES INCLUDED DISEASE ACTIVITY (RACHMILEWITZ CLINICAL ACTIVITY INDEX) AND SAFETY. OUTCOMES WERE ASSESSED AT WEEKS 12 AND 24 BY BLINDED OUTCOME ASSESSORS. RESULTS: THE YOGA GROUP HAD SIGNIFICANTLY HIGHER DISEASE-SPECIFIC QUALITY OF LIFE COMPARED TO THE SELF-CARE GROUP AFTER 12 WEEKS (DELTA = 14.6; 95% CONFIDENCE INTERVAL=2.6-26.7; P = 0.018) AND AFTER 24 WEEKS (DELTA = 16.4; 95% CONFIDENCE INTERVAL=2.5-30.3; P = 0.022). TWENTY-ONE AND 12 PATIENTS IN THE YOGA GROUP AND IN THE SELF-CARE GROUP, RESPECTIVELY, REACHED A CLINICAL RELEVANT INCREASE IN QUALITY OF LIFE AT WEEK 12 (P = 0.048); AND 27 AND 17 PATIENTS AT WEEK 24 (P = 0.030). DISEASE ACTIVITY WAS LOWER IN THE YOGA GROUP COMPARED TO THE SELF-CARE GROUP AFTER 24 WEEKS (DELTA = -1.2; 95% CONFIDENCE INTERVAL=-0.1-[-2.3]; P = 0.029). THREE AND ONE PATIENT IN THE YOGA GROUP AND IN THE SELF-CARE GROUP, RESPECTIVELY, EXPERIENCED SERIOUS ADVERSE EVENTS (P = 0.317); AND SEVEN AND EIGHT PATIENTS EXPERIENCED NONSERIOUS ADVERSE EVENTS (P = 0.731). CONCLUSIONS: YOGA CAN BE CONSIDERED AS A SAFE AND EFFECTIVE ANCILLARY INTERVENTION FOR PATIENTS WITH ULCERATIVE COLITIS AND IMPAIRED QUALITY OF LIFE. TRIAL REGISTRATION: CLINICALTRIALS.GOV IDENTIFIER: NCT02043600.	2017	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
11 1861  34 RANDOMIZED CONTROLLED TRIAL OF BIKRAM YOGA AND AEROBIC EXERCISE FOR DEPRESSION IN WOMEN: EFFICACY AND STRESS-BASED MECHANISMS. BACKGROUND: THE CURRENT STUDY PRESENTS A RANDOMIZED CONTROLLED 8-WEEK TRIAL OF BIKRAM YOGA, AEROBIC EXERCISE, AND WAITLIST FOR DEPRESSION. BIKRAM YOGA WAS CHOSEN SPECIFICALLY FOR ITS STANDARDIZED NATURE. FURTHER, WE EXAMINED CHANGES IN THREE STRESS-RELATED CONSTRUCTS-PERCEIVED STRESS, RUMINATION, AND MINDFULNESS-AS MEDIATORS OF ANTIDEPRESSANT EFFECTS. METHOD: FIFTY-THREE WOMEN (AGE 18-65; 74% WHITE) WITH A UNIPOLAR DEPRESSIVE DISORDER WERE RANDOMLY ASSIGNED TO ONE OF THE THREE CONDITIONS. RESPONSE WAS DEFINED AS >50% REDUCTION ON THE HAMILTON RATING SCALE FOR DEPRESSION (HAM-D). REMISSION WAS DEFINED AS NO LONGER MEETING CRITERIA FOR DEPRESSION AND A HAM-D </= 7. SELF-REPORTED PERCEIVED STRESS, RUMINATION, AND MINDFULNESS WERE ASSESSED WEEKLY. RESULTS: IN THE INTENTION-TO-TREAT SAMPLE (N = 53), RESPONSE RATES WERE SIGNIFICANTLY HIGHER IN THE BIKRAM YOGA (61.1%; CHI(2) = 10.48, P = .001) AND AEROBIC EXERCISE (60.0%; CHI(2) = 10.44, P = .001) CONDITIONS RELATIVE TO WAITLIST (6.7%). IN THE COMPLETER SAMPLE (N = 42), 73.3% (CHI(2) = 11.41, P = .001) OF WOMEN IN YOGA AND 80.0% (CHI(2) = 13.72, P < .001) IN EXERCISE ACHIEVED RESPONSE COMPARED TO 8.3% IN WAITLIST. REDUCTIONS IN RUMINATION SIGNIFICANTLY MEDIATED HAM-D CHANGE FOR BOTH ACTIVE TREATMENTS, AND MINDFUL ACCEPTANCE WAS A PARTIAL MEDIATOR IN THE EXERCISE CONDITION. LIMITATIONS: THE SAMPLE WAS SMALL IN SIZE, CONSISTED OF WOMEN ONLY, AND WAS ETHNICALLY HOMOGENOUS. INTER-RATER RELIABILITY WAS NOT ASSESSED, AEROBIC EXERCISE WAS NOT STANDARDIZED, AND MEDIATORS WERE ASSESSED BY SELF-REPORT. CONCLUSIONS: BIKRAM YOGA SHOWED DESCRIPTIVELY SIMILAR EFFICACY TO AEROBIC EXERCISE AND BOTH MAY WORK, IN PART, BY HELPING INDIVIDUALS INTERRUPT NEGATIVE THINKING.	2021	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
12  745  33 EFFECT OF SAHAJ YOGA ON DEPRESSIVE DISORDERS. SAHAJ YOGA IS A MEDITATIVE TECHNIQUE THAT HAS BEEN FOUND TO HAVE BENEFICIAL EFFECTS IN SOME PSYCHO-SOMATIC ILLNESSES. THE STUDY WAS CARRIED OUT ON 30 CASES (19 MALES, 11 FEMALES, AGE 18-45 YEARS) OF MAJOR DEPRESSION DIAGNOSED ON THE BASIS OF DSM IV CRITERIA. THE PATIENTS WERE THEN RANDOMLY DIVIDED INTO TWO GROUPS: GROUP 1: (10 MALES & 5 FEMALES) PATIENTS WHO WERE PRACTISING SAHAJ YOGA AND ALSO RECEIVED CONVENTIONAL ANTI-DEPRESSANTS. GROUP 2: (9 MALES & 6 FEMALES) PATIENTS WHO WERE ONLY RECEIVING CONVENTIONAL ANTI-DEPRESSANTS. TRAINING IN SAHAJ YOGA WAS CONDUCTED UNDER THE SUPERVISION OF A TRAINED SAHAJ YOGI FOR 8 WEEKS. AT START OF THE STUDY, ALL THE PATIENTS WERE SUBJECTED TO HAMILTON RATING SCALE FOR DEPRESSION (HAM-D) AND HAMILTON RATING SCALE FOR ANXIETY (HAM-A). ABOVE SCALES WERE AGAIN ASSESSED AFTER TWO MONTHS OF TREATMENT. THERE WAS SIGNIFICANT IMPROVEMENT IN HAM-D AS WELL AS HAM-A SCORES IN BOTH GROUP 1 AND GROUP 2 PATIENTS (P<0.001). HOWEVER, PERCENTAGE IMPROVEMENT IN HAM-D SCORES AND HAM-A SCORES IN PATIENTS RECEIVING SAHAJ YOGA WAS SIGNIFICANTLY HIGHER THAN IN GROUP 2 PATIENTS. THE NUMBER OF PATIENTS WHO WENT INTO REMISSION AFTER TWO MONTHS OF INTERVENTION WERE ALSO SIGNIFICANTLY HIGHER IN GROUP 1 PATIENTS (P=0.02). THE PRESENT STUDY DEMONSTRATES THAT SAHAJ YOGA HAS GOT A POTENTIAL ROLE AS A COMPONENT IN THE MANAGEMENT OF DEPRESSIVE DISORDERS.	2005	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
13 1544  50 KUNDALINI YOGA MEDITATION VERSUS THE RELAXATION RESPONSE MEDITATION FOR TREATING ADULTS WITH OBSESSIVE-COMPULSIVE DISORDER: A RANDOMIZED CLINICAL TRIAL. BACKGROUND: OBSESSIVE-COMPULSIVE DISORDER (OCD) IS OFTEN A LIFE-LONG DISORDER WITH HIGH PSYCHOSOCIAL IMPAIRMENT. SEROTONIN REUPTAKE INHIBITORS (SRIS) ARE THE ONLY FDA APPROVED DRUGS, AND APPROXIMATELY 50% OF PATIENTS ARE NON-RESPONDERS WHEN USING A CRITERION OF 25% TO 35% IMPROVEMENT WITH THE YALE-BROWN OBSESSIVE-COMPULSIVE SCALE (Y-BOCS). ABOUT 30% ARE NON-RESPONDERS TO COMBINED FIRST-LINE THERAPIES (SRIS AND EXPOSURE AND RESPONSE PREVENTION). PREVIOUS RESEARCH (ONE OPEN, ONE RANDOMIZED CLINICAL TRIAL) HAS DEMONSTRATED THAT KUNDALINI YOGA (KY) MEDITATION CAN LEAD TO AN IMPROVEMENT IN SYMPTOMS OF OBSESSIVE-COMPULSIVE SEVERITY. WE EXPAND HERE WITH A LARGER TRIAL. DESIGN: THIS TRIAL COMPARED TWO PARALLEL RUN GROUPS [KY VS. RELAXATION RESPONSE MEDITATION (RR)]. PATIENTS WERE RANDOMLY ALLOCATED BASED ON GENDER AND Y-BOCS SCORES. THEY WERE TOLD TWO DIFFERENT (UNNAMED) TYPES OF MEDITATION WOULD BE COMPARED, AND INFORMED IF ONE SHOWED GREATER BENEFITS, THE GROUPS WOULD MERGE FOR 12 MONTHS USING THE MORE EFFECTIVE INTERVENTION. RATERS WERE BLIND IN PHASE ONE (0-4.5 MONTHS) TO PATIENT ASSIGNMENTS, BUT NOT IN PHASE TWO. MAIN OUTCOME MEASURES: PRIMARY OUTCOME VARIABLE, CLINICIAN-ADMINISTERED Y-BOCS. SECONDARY SCALES: DIMENSIONAL YALE-BROWN OBSESSIVE COMPULSIVE SCALE (CLINICIAN-ADMINISTERED), PROFILE OF MOOD SCALES, BECK ANXIETY INVENTORY, BECK DEPRESSION INVENTORY, CLINICAL GLOBAL IMPRESSION, SHORT FORM 36 HEALTH SURVEY. RESULTS: PHASE ONE: BASELINE Y-BOCS SCORES: KY MEAN = 26.46 (SD 5.124; N = 24), RR MEAN = 26.79 (SD = 4.578; N = 24). AN INTENT-TO-TREAT ANALYSIS WITH THE LAST OBSERVATION CARRIED FORWARD FOR DROPOUTS SHOWED STATISTICALLY GREATER IMPROVEMENT WITH KY COMPARED TO RR ON THE Y-BOCS, AND STATISTICALLY GREATER IMPROVEMENT ON FIVE OF SIX SECONDARY MEASURES. FOR COMPLETERS, THE Y-BOCS SHOWED 40.4% IMPROVEMENT FOR KY (N = 16), 17.9% FOR RR (N = 11); 31.3% IN KY WERE JUDGED TO BE IN REMISSION COMPARED TO 9.1% IN RR. KY COMPLETERS SHOWED GREATER IMPROVEMENT ON FIVE OF SIX SECONDARY MEASURES. AT THE END OF PHASE TWO (12 MONTHS), PATIENTS, DRAWN FROM THE INITIAL GROUPS, WHO ELECTED TO RECEIVE KY CONTINUED TO SHOW IMPROVEMENT IN THEIR Y-BOCS SCORES. CONCLUSION: KY SHOWS PROMISE AS AN ADD-ON OPTION FOR OCD PATIENTS UNRESPONSIVE TO FIRST LINE THERAPIES. FUTURE STUDIES WILL ESTABLISH KY'S RELATIVE EFFICACY COMPARED TO EXPOSURE AND RESPONSE PREVENTION AND/OR MEDICATIONS, AND THE MOST EFFECTIVE TREATMENT SCHEDULE. CLINICAL TRIAL REGISTRATION: WWW.CLINICALTRIALS.GOV, IDENTIFIER NCT01833442.	2019	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
14  978  55 EFFECTS OF BODY-ORIENTED YOGA: A RCT STUDY FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER. THE MAJOR DEPRESSIVE DISORDER IS ONE OF THE MOST COMMON MENTAL ILLNESSES WORLDWIDE. CURRENT TREATMENT STANDARDS RECOMMEND A COMBINED THERAPY WITH MEDICATION AND PSYCHOTHERAPY. AS AN ADDITIVE COMPONENT AND TO FURTHER IMPROVEMENTS IN TREATMENT, PHYSICAL ACTIVITY SUCH AS YOGA MAY BE INTEGRATED INTO CONVENTIONAL TREATMENT. THIS STUDY INVESTIGATES THE IMPACT OF A 3-MONTH BODY-ORIENTED YOGA IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD). IN TOTAL, N = 83 PATIENTS WERE INCLUDED. AN INTERVENTION GROUP RECEIVED A VIGOROUS ASHTANGA-YOGA THREE TIMES A WEEK. THE WAITING-LIST CONTROL GROUP OBTAINED A TREATMENT AS USUAL (TAU). AS A PRIMARY OUTCOME DEPRESSION SCORES (BECK DEPRESSION INVENTORY-II (BDI-II), MONTGOMERY ASBERG DEPRESSION RATING SCALE (MADRS)) WERE TESTED AT THREE TIME POINTS. SECONDARY OUTCOME WAS THE POSITIVE AND NEGATIVE AFFECT [POSITIVE AND NEGATIVE AFFECT SCALE (PANAS)] AND REMISSION RATES. TO ANALYZE THE DATA, MULTILEVEL MODELS AND EFFECT SIZES WERE CONDUCTED. THE RESULTS SHOWED AN IMPROVEMENT IN BDI-II SCORES FOR BOTH GROUPS OVER TIME [GAMMA = - 3.46, T(165) = - 7.99, P < 0.001] BUT NOT BETWEEN GROUPS [GAMMA = 0.98, T(164) = 1.12, P = 0.263]. AN INTERACTION EFFECT (TIME X GROUP) OCCURRED FOR MADRS [GAMMA = 2.10, T(164) = 2.10, P < 0.038]. POSITIVE AFFECTS IMPROVED OVER TIME FOR BOTH GROUPS [GAMMA = 1.65, T(165) = 4.03, P < 0.001]. NEGATIVE AFFECTS DECREASED FOR ALL OVER TIME [GAMMA = - 1.00, T(165) = - 2.51, P = 0.013]. THERE WERE NO SIGNIFICANT GROUP DIFFERENCES IN PANAS. POST HOC TESTS REVEALED A GREATER SYMPTOM REDUCTION WITHIN THE FIRST 6 WEEKS FOR ALL MEASUREMENTS. THE EFFECT SIZES FOR DEPRESSION SCORES SHOWED A POSITIVE TREND. REMISSION RATES INDICATED A SIGNIFICANT IMPROVEMENT IN THE YOGA GROUP (BDI-II: 46.81%, MADRS: 17.02%) COMPARED TO THE CONTROL GROUP (BDI: 33.33%, MADRS: 8.33%). THE FINDINGS SUGGEST THAT THERE IS A TRENDSETTING ADDITIVE EFFECT OF ASHTANGA-YOGA AFTER 3 MONTHS ON PSYCHOPATHOLOGY AND MOOD WITH A GREATER IMPROVEMENT AT THE BEGINNING OF THE INTERVENTION. FURTHER RESEARCH IN THIS FIELD CAN HELP TO ACHIEVE MORE DIFFERENTIATED RESULTS.	2021	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
15 1831  64 PSYCHOLOGICAL FUNCTION, IYENGAR YOGA, AND COHERENT BREATHING: A RANDOMIZED CONTROLLED DOSING STUDY. BACKGROUND: EVIDENCE SUGGESTS THAT YOGA MAY BE AN EFFECTIVE TREATMENT FOR MAJOR DEPRESSIVE DISORDER (MDD). STUDIES EVALUATING THE "DOSING" OF YOGA TREATMENT AND EFFICACY FOR MDD ARE NEEDED. THE GOAL OF THIS STUDY WAS TO ASSESS THE EFFECTS OF AN INTERVENTION COMBINING IYENGAR YOGA AND COHERENT BREATHING IN PARTICIPANTS WITH MDD AND DETERMINE THE OPTIMAL INTERVENTION DOSE. METHODS: THIRTY-TWO PARTICIPANTS (18 TO 65 Y OF AGE) DIAGNOSED WITH MDD WERE RANDOMIZED TO A HIGH-DOSE GROUP (HDG) OR A LOW-DOSE GROUP (LDG) OF YOGA AND COHERENT BREATHING FOR 12 WEEKS. THE HDG (N=15) INVOLVED THREE 90-MINUTE YOGA CLASSES AND FOUR 30-MINUTE HOMEWORK SESSIONS PER WEEK. THE LDG (N=15) INVOLVED TWO 90-MINUTE YOGA CLASSES AND THREE 30-MINUTE HOMEWORK SESSIONS PER WEEK. PARTICIPANTS WERE EVALUATED AT BASELINE, WEEK 4, WEEK 8, AND WEEK 12 WITH THE FOLLOWING INSTRUMENTS: POSITIVITY SELF-TEST, SPIELBERGER STATE ANXIETY INVENTORY, PATIENT HEALTH QUESTIONNAIRE-9, PITTSBURGH SLEEP QUALITY INDEX, AND EXERCISE-INDUCED FEELING INVENTORY. DATA WERE ANALYZED USING INTENT-TO-TREAT METHODS. RESULTS: SIGNIFICANT IMPROVEMENTS IN ALL OUTCOME MEASURES WERE FOUND FOR BOTH GROUPS, WITH ACUTE AND CUMULATIVE BENEFITS. ALTHOUGH THE HDG SHOWED GREATER IMPROVEMENTS ON ALL SCALES, BETWEEN-GROUP DIFFERENCES DID NOT REACH SIGNIFICANCE, POSSIBLY DUE TO LACK OF POWER BECAUSE OF THE SMALL SAMPLE SIZE. CUMULATIVE YOGA MINUTES WERE CORRELATED WITH IMPROVEMENT IN OUTCOME MEASURES. LIMITATION: THIS DOSING STUDY DID NOT INCLUDE A NON-YOGA CONTROL. CONCLUSIONS: IMPROVEMENT IN PSYCHOLOGICAL SYMPTOMS CORRELATED WITH CUMULATIVE YOGA PRACTICE. BOTH INTERVENTIONS REDUCED SYMPTOMS OF DEPRESSION AND ANXIETY AND INCREASED FEELINGS OF POSITIVITY. THE TIME COMMITMENT FOR YOGA PRACTICE NEEDS TO BE WEIGHED AGAINST BENEFITS WHEN DESIGNING YOGA INTERVENTIONS.	2019	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
16  891  37 EFFECT OF YOGA-BASED INTERVENTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. BACKGROUND: INFLAMMATORY BOWEL DISEASE (IBD) IS A CHRONIC ILLNESS CHARACTERIZED BY GROSS INFLAMMATION IN THE GASTROINTESTINAL TRACT THAT CAN RESULT IN SYMPTOMS SUCH AS ABDOMINAL PAIN, CRAMPING, DIARRHEA, AND BLOODY STOOLS. IBD IS BELIEVED TO BE INFLUENCED BY PSYCHOLOGICAL FACTORS SUCH AS STRESS AND ANXIETY. THEREFORE, A YOGA INTERVENTION THAT REDUCES STRESS AND ANXIETY MAY BE AN EFFECTIVE COMPLEMENTARY TREATMENT FOR THESE DISORDERS. MATERIAL AND METHODS: A TOTAL OF 100 IBD PATIENTS [ULCERATIVE COLITIS (UC) N = 60 AND CROHN'S DISEASE (CD) N = 40] DURING THE CLINICAL REMISSION PHASE OF DISEASE WERE INCLUDED IN THE STUDY. THESE PATIENTS WERE ALLOCATED RANDOMLY TO EITHER THE YOGA GROUP THAT UNDERWENT AN 8-WEEK YOGA INTERVENTION (PHYSICAL POSTURES, PRANAYAMA, AND MEDITATION) 1- HOUR/DAY IN ADDITION TO STANDARD MEDICAL THERAPY (UC, N = 30; CD, N = 20) OR THE CONTROL GROUP (UC, N = 30; CD N = 20), WHICH CONTINUED WITH STANDARD MEDICAL THERAPY ALONE. THE MAIN OUTCOME MEASURES WERE CARDIOVASCULAR AUTONOMIC FUNCTIONS, SERUM EOSINOPHILIC CATIONIC PROTEIN, INTERLEUKIN- 2 SOLUBLE RECEPTORS, SPEILBERGER'S STATE TRAIT ANXIETY INVENTORY (STAI) SCORES, AND CLINICAL SYMPTOMS. RESULTS: BEFORE THE INTERVENTION, ALL THE OUTCOME MEASURES WERE COMPARABLE IN THE TWO GROUPS. AFTER THE 8-WEEK YOGA INTERVENTION, FEWER UC PATIENTS REPORTED ARTHRALGIA. THE NUMBER OF PATIENTS REPORTING INTESTINAL COLIC PAIN IN THE CONTROL GROUP WAS HIGHER. STATE AND TRAIT ANXIETY LEVELS WERE SIGNIFICANTLY REDUCED IN PATIENTS WITH UC. HOWEVER, NO SIGNIFICANT CHANGES WERE OBSERVED IN CARDIOVASCULAR AUTONOMIC FUNCTIONS, EOSINOPHILIC CATIONIC PROTEINS, OR INTERLEUKIN-2 SOLUBLE RECEPTORS. CONCLUSIONS: A SIMPLIFIED YOGA-BASED REGIMEN IS A SAFE AND EFFECTIVE COMPLEMENTARY CLINICAL TREATMENT MODALITY FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE DURING THE CLINICAL REMISSION PHASE.	2015	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
17 2854  46 YOGA- AND MEDITATION-BASED LIFESTYLE INTERVENTION INCREASES NEUROPLASTICITY AND REDUCES SEVERITY OF MAJOR DEPRESSIVE DISORDER: A RANDOMIZED CONTROLLED TRIAL. BACKGROUND: CURRENT INTERVENTIONS FOR MAJOR DEPRESSIVE DISORDER (MDD) ARE SUBOPTIMAL, AND ONLY ONE THIRD RESPOND TO THEM ON INITIAL TREATMENT. NEUROPLASTICITY THEORIES ARE THE BASIS FOR SEVERAL EMERGING TREATMENTS. EVIDENCE ON THE IMPACT OF YOGA, A WELL-KNOWN MIND-BODY INTERVENTION, ON NEUROPLASTICITY IN MDD IS LIMITED. OBJECTIVES: TO DETERMINE THE EFFECTS OF 12-WEEK YOGA- AND MEDITATION-BASED LIFESTYLE INTERVENTION (YMLI) ON DEPRESSION SEVERITY AND SYSTEMIC BIOMARKERS OF NEUROPLASTICITY IN ADULT MDD PATIENTS ON ROUTINE DRUG TREATMENT. METHODS: A TOTAL OF 58 MDD PATIENTS WERE RANDOMIZED INTO YOGA OR CONTROL GROUP. THE SEVERITY OF DEPRESSION WAS ASSESSED WITH BECK DEPRESSION INVENTORY-II SCALE (BDI-II). BLOOD SAMPLES WERE COLLECTED BEFORE AND AFTER INTERVENTION FOR THE MEASUREMENT OF THE BIOMARKERS THAT CHARACTERIZE NEUROPLASTICITY, INCLUDING MIND-BODY COMMUNICATIVE AND CELLULAR HEALTH BIOMARKERS. RESULTS: THERE WAS A SIGNIFICANT DECREASE [DIFFERENCE BETWEEN MEANS, (95% CI)] IN BDI-II SCORE [-5.83 (-7.27, -4.39), P < 0.001] AND SIGNIFICANT INCREASE IN BDNF (NG/ML) [5.48 (3.50, 7.46), P < 0.001] AFTER YMLI COMPARED TO CONTROL GROUP. YMLI SIGNIFICANTLY INCREASED DHEAS, SIRTUIN 1, AND TELOMERASE ACTIVITY LEVELS, AND DECREASED CORTISOL, AND IL-6 LEVELS, IN ADDITION TO DECREASING DNA DAMAGE AND BALANCING OXIDATIVE STRESS. MULTIPLE REGRESSION ANALYSES WERE USED TO ASSOCIATE NEUROPLASTICITY BIOMARKERS WITH DEPRESSION SEVERITY. A 'POST-INTERVENTION CHANGE IN BDNF' X 'GROUP' INTERACTION INDICATED THAT YOGA GROUP HAD MORE BDNF IN ASSOCIATION WITH LESS BDI-II SCORES RELATIVE TO CONTROLS. INCREASED SIRTUIN 1 AND TELOMERASE ACTIVITY AND DECREASED CORTISOL SIGNIFICANTLY PREDICTED THIS ASSOCIATION (ALL P < 0.05). CONCLUSION: THESE RESULTS SUGGEST THAT DECREASE IN DEPRESSION SEVERITY AFTER YMLI IN MDD IS ASSOCIATED WITH IMPROVED SYSTEMIC BIOMARKERS OF NEUROPLASTICITY. THUS YMLI CAN BE CONSIDERED AS A THERAPEUTIC INTERVENTION IN MDD MANAGEMENT.	2018	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
18 1597  36 MEDITATION WITH YOGA, GROUP THERAPY WITH HYPNOSIS, AND PSYCHOEDUCATION FOR LONG-TERM DEPRESSED MOOD: A RANDOMIZED PILOT TRIAL. THIS RANDOMIZED PILOT STUDY INVESTIGATED THE EFFECTS OF MEDITATION WITH YOGA (AND PSYCHOEDUCATION) VERSUS GROUP THERAPY WITH HYPNOSIS (AND PSYCHOEDUCATION) VERSUS PSYCHOEDUCATION ALONE ON DIAGNOSTIC STATUS AND SYMPTOM LEVELS AMONG 46 INDIVIDUALS WITH LONG-TERM DEPRESSIVE DISORDERS. RESULTS INDICATE THAT SIGNIFICANTLY MORE MEDITATION GROUP PARTICIPANTS EXPERIENCED A REMISSION THAN DID CONTROLS AT 9-MONTH FOLLOW-UP. EIGHT HYPNOSIS GROUP PARTICIPANTS ALSO EXPERIENCED A REMISSION, BUT THE DIFFERENCE FROM CONTROLS WAS NOT STATISTICALLY SIGNIFICANT. THREE CONTROL PARTICIPANTS, BUT NO MEDITATION OR HYPNOSIS PARTICIPANTS, DEVELOPED A NEW DEPRESSIVE EPISODE DURING THE STUDY, THOUGH THIS DIFFERENCE DID NOT REACH STATISTICAL SIGNIFICANCE IN ANY CASE. ALTHOUGH ALL GROUPS REPORTED SOME REDUCTION IN SYMPTOM LEVELS, THEY DID NOT DIFFER SIGNIFICANTLY IN THAT OUTCOME. OVERALL, THESE RESULTS SUGGEST THAT THESE TWO INTERVENTIONS SHOW PROMISE FOR TREATING LOW- TO MODERATE-LEVEL DEPRESSION.	2008	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
19 2518  49 YOGA COMPARED TO NON-EXERCISE OR PHYSICAL THERAPY EXERCISE ON PAIN, DISABILITY, AND QUALITY OF LIFE FOR PATIENTS WITH CHRONIC LOW BACK PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. BACKGROUND: CHRONIC LOW BACK PAIN (CLBP) IS A COMMON AND OFTEN DISABLING MUSCULOSKELETAL CONDITION. YOGA HAS BEEN PROVEN TO BE AN EFFECTIVE THERAPY FOR CHRONIC LOW BACK PAIN. HOWEVER, THERE ARE STILL CONTROVERSIES ABOUT THE EFFECTS OF YOGA AT DIFFERENT FOLLOW-UP PERIODS AND COMPARED WITH OTHER PHYSICAL THERAPY EXERCISES. OBJECTIVE: TO CRITICALLY COMPARE THE EFFECTS OF YOGA FOR PATIENTS WITH CHRONIC LOW BACK PAIN ON PAIN, DISABILITY, QUALITY OF LIFE WITH NON-EXERCISE (E.G. USUAL CARE, EDUCATION), PHYSICAL THERAPY EXERCISE. METHODS: THIS STUDY WAS REGISTERED IN PROSPERO, AND THE REGISTRATION NUMBER WAS CRD42020159865. RANDOMIZED CONTROLLED TRIALS (RCTS) OF ONLINE DATABASES INCLUDED PUBMED, WEB OF SCIENCE, COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS, EMBASE WHICH EVALUATED EFFECTS OF YOGA FOR PATIENTS WITH CHRONIC LOW BACK PAIN ON PAIN, DISABILITY, AND QUALITY OF LIFE WERE SEARCHED FROM INCEPTION TIME TO NOVEMBER 1, 2019. STUDIES WERE ELIGIBLE IF THEY ASSESSED AT LEAST ONE IMPORTANT OUTCOME, NAMELY PAIN, BACK-SPECIFIC DISABILITY, QUALITY OF LIFE. THE COCHRANE RISK OF BIAS TOOL WAS USED TO ASSESS THE METHODOLOGICAL QUALITY OF INCLUDED RANDOMIZED CONTROLLED TRIALS. THE CONTINUOUS OUTCOMES WERE ANALYZED BY CALCULATING THE MEAN DIFFERENCE (MD) OR STANDARDIZED MEAN DIFFERENCE (SMD) WITH 95% CONFIDENCE INTERVALS (CI) ACCORDING TO WHETHER COMBINING OUTCOMES MEASURED ON DIFFERENT SCALES OR NOT. RESULTS: A TOTAL OF 18 RANDOMIZED CONTROLLED TRIALS WERE INCLUDED IN THIS META-ANALYSIS. YOGA COULD SIGNIFICANTLY REDUCE PAIN AT 4 TO 8 WEEKS (MD = -0.83, 95% CI = -1.19 TO -0.48, P<0.00001, I2 = 0%), 3 MONTHS (MD = -0.43, 95% CI = -0.64 TO -0.23, P<0.0001, I2 = 0%), 6 TO 7 MONTHS (MD = -0.56, 95% CI = -1.02 TO -0.11, P = 0.02, I2 = 50%), AND WAS NOT SIGNIFICANT IN 12 MONTHS (MD = -0.52, 95% CI = -1.64 TO 0.59, P = 0.36, I2 = 87%) COMPARED WITH NON-EXERCISE. YOGA WAS BETTER THAN NON-EXERCISE ON DISABILITY AT 4 TO 8 WEEKS (SMD = -0.30, 95% CI = -0.51 TO -0.10, P = 0.003, I2 = 0%), 3 MONTHS (SMD = -0.31, 95% CI = -0.45 TO -0.18, P<0.00001, I2 = 30%), 6 MONTHS (SMD = -0.38, 95% CI = -0.53 TO -0.23, P<0.00001, I2 = 0%), 12 MONTHS (SMD = -0.33, 95% CI = -0.54 TO -0.12, P = 0.002, I2 = 9%). THERE WAS NO SIGNIFICANT DIFFERENCE ON PAIN, DISABILITY COMPARED WITH PHYSICAL THERAPY EXERCISE GROUP. FURTHERMORE, IT SUGGESTED THAT THERE WAS A NON-SIGNIFICANT DIFFERENCE ON PHYSICAL AND MENTAL QUALITY OF LIFE BETWEEN YOGA AND ANY OTHER INTERVENTIONS. CONCLUSION: THIS META-ANALYSIS PROVIDED EVIDENCE FROM VERY LOW TO MODERATE INVESTIGATING THE EFFECTIVENESS OF YOGA FOR CHRONIC LOW BACK PAIN PATIENTS AT DIFFERENT TIME POINTS. YOGA MIGHT DECREASE PAIN FROM SHORT TERM TO INTERMEDIATE TERM AND IMPROVE FUNCTIONAL DISABILITY STATUS FROM SHORT TERM TO LONG TERM COMPARED WITH NON-EXERCISE (E.G. USUAL CARE, EDUCATION). YOGA HAD THE SAME EFFECT ON PAIN AND DISABILITY AS ANY OTHER EXERCISE OR PHYSICAL THERAPY. YOGA MIGHT NOT IMPROVE THE PHYSICAL AND MENTAL QUALITY OF LIFE BASED ON THE RESULT OF A MERGING.	2020	

20 2415  44 YOGA AND MEDITATION FOR MENOPAUSAL SYMPTOMS IN BREAST CANCER SURVIVORS-A RANDOMIZED CONTROLLED TRIAL. BACKGROUND: BREAST CANCER SURVIVORS HAVE ONLY VERY LIMITED TREATMENT OPTIONS FOR MENOPAUSAL SYMPTOMS. THE OBJECTIVE OF THIS TRIAL WAS TO EVALUATE THE EFFECTS OF A 12-WEEK TRADITIONAL HATHA YOGA AND MEDITATION INTERVENTION ON MENOPAUSAL SYMPTOMS IN BREAST CANCER SURVIVORS. METHODS: PATIENTS WERE RANDOMLY ASSIGNED EITHER TO A 12-WEEK YOGA AND MEDITATION INTERVENTION OR TO USUAL CARE. THE PRIMARY OUTCOME MEASURE WAS TOTAL MENOPAUSAL SYMPTOMS (MENOPAUSE RATING SCALE [MRS] TOTAL SCORE). SECONDARY OUTCOME MEASURES INCLUDED MRS SUBSCALES, QUALITY OF LIFE (FUNCTIONAL ASSESSMENT OF CANCER THERAPY-BREAST), FATIGUE (FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE), DEPRESSION, AND ANXIETY (HOSPITAL ANXIETY AND DEPRESSION SCALE). OUTCOMES WERE ASSESSED AT WEEK 12 AND WEEK 24 AFTER RANDOMIZATION. RESULTS: IN TOTAL, 40 WOMEN (MEAN AGE +/- STANDARD DEVIATION, 49.2 +/- 5.9 YEARS) WERE RANDOMIZED TO YOGA (N = 19) OR TO USUAL CARE (N = 21). WOMEN IN THE YOGA GROUP REPORTED SIGNIFICANTLY LOWER TOTAL MENOPAUSAL SYMPTOMS COMPARED WITH THE USUAL CARE GROUP AT WEEK 12 (MEAN DIFFERENCE, -5.6; 95% CONFIDENCE INTERVAL, -9.2 TO -1.9; P = .004) AND AT WEEK 24 (MEAN DIFFERENCE, -4.5; 95% CONFIDENCE INTERVAL, -8.3 TO -0.7; P = .023). AT WEEK 12, THE YOGA GROUP REPORTED LESS SOMATOVEGETATIVE, PSYCHOLOGICAL, AND UROGENITAL MENOPAUSAL SYMPTOMS; LESS FATIGUE; AND IMPROVED QUALITY OF LIFE (ALL P < .05). AT WEEK 24, ALL EFFECTS PERSISTED EXCEPT FOR PSYCHOLOGICAL MENOPAUSAL SYMPTOMS. SHORT-TERM EFFECTS ON MENOPAUSAL SYMPTOMS REMAINED SIGNIFICANT WHEN ONLY WOMEN WHO WERE RECEIVING ANTIESTROGEN MEDICATION (N = 36) WERE ANALYZED. SIX MINOR ADVERSE EVENTS OCCURRED IN EACH GROUP. CONCLUSIONS: YOGA COMBINED WITH MEDITATION CAN BE CONSIDERED A SAFE AND EFFECTIVE COMPLEMENTARY INTERVENTION FOR MENOPAUSAL SYMPTOMS IN BREAST CANCER SURVIVORS. THE EFFECTS SEEM TO PERSIST FOR AT LEAST 3 MONTHS.	2015